Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
Globe Newswire•14/10/2026•07:00 ET
0
Key Highlights
- ➤DMC recommends Cohort 3 initiation at 18 mg/kg, up from 12 mg/kg
- ➤Cohort 2 enrollment complete; data expected in Q1 2027
- ➤Cohort 1 open-label data expected by year-end 2026
- ➤ELEVATE-44-201 evaluates ENTR-601-44 in exon 44-skipping Duchenne patients
Expert Statements
Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics
“The independent Data Monitoring Committee’s recommendation to advance to Cohort 3 at the top dose of 18 mg/kg marks another important step in the clinical development of ENTR-601-44”
Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics
“This recommendation allows us to continue dose escalation in the ELEVATE-44-201 clinical study and deepen our understanding of ENTR-601-44’s safety, pharmacokinetic and pharmacodynamic profile, as dosing at 18 mg/kg could lead to meaningfully higher exposure, dystrophin production and functional benefit.”
Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics
“We look forward to receiving data later this year from Cohort 1 participants after one year of treatment in the open-label period, followed by Cohort 2 data in the first quarter of 2027.”
-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --
-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --
Get started
Create a free account to read the full story.